Profitable at the Micro-Cap Level, But the Audit Question Looms
Research Assessment
Analysis
BioStem is one of the few companies in this group that is actually profitable on an adjusted basis, and that matters. Gross margins near 90% are not theoretical. They are real, repeatable, and difficult to ignore. At the same time, the unresolved audit and restated financials hang over the stock like a question that cannot be dodged.
What keeps this investable is not trust, it's economics. If the audit validates the numbers, the upside re-opens quickly. If it doesn't, the story breaks. Until that question is answered, this is a business worth watching, not blindly believing.
Bottom line: The economics are real. The audit is the gating factor. Watch for resolution before sizing up.
Back to the Library
MetriNote
The journal that tracks your psychology, not just your P&L. Break a rule? Accountability Mode flags it and shows you exactly what it cost. Futures, forex, stocks, crypto, CFDs, options.
Paid Advertisement. This research profile was prepared by WLW Holdings LLC on behalf of BioStem Technologies (BSEM), which has compensated WLW Holdings LLC for the preparation and distribution of this content. This is a paid advertisement pursuant to Section 17(b) of the Securities Act of 1933, as amended. WLW Holdings LLC has not been compensated for trading in the referenced securities and does not currently hold a position in BSEM. This content is for informational purposes only and does not constitute financial, investment, or legal advice. All investments involve risk, including the potential loss of principal. Micro-cap and OTC securities carry additional risks including limited liquidity, limited disclosure, and high volatility. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Past performance does not guarantee future results.